DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors
(Thomson Reuters ONE) -
Press Release
Montrouge, France, June 15, 2017
DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) announced today that Julie O'Neill has been appointed to the Company's
Board of Directors, effective immediately pursuant to her election at the
Company's Ordinary and Extraordinary General Meeting in Montrouge, France. With
this addition, DBV's Board now comprises eight directors.
Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV
Technologies, said: "Ms. O'Neill is an accomplished leader who brings her vast
experience and knowledge of the biopharmaceutical industry to our Board. Her
complementary expertise in manufacturing and quality operations will enable her
to make significant contributions during this pivotal time for the Phase III
Viaskin Peanut development program and DBV."
Ms. O'Neill is expected to serve on the Board for a period of two years. She is
currently Executive Vice President, Global Operations of Alexion, responsible
for global manufacturing operations, as well as Alexion's complete supply chain
and quality operations. Before joining Alexion, she was Vice President of
Operations and General Manager for Ireland at Gilead. Earlier in her career, Ms.
O'Neill held leadership positions in operations, manufacturing and quality
functions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She also
serves as Chairperson for the National Standards Authority of Ireland and is a
member of the Governing Body of University College Cork.
"I am honored and excited to join the Board of DBV," said Ms. Julie O'Neill.
"Throughout my career, I have held leadership positions in biopharmaceutical
operations, manufacturing, supply chain and quality control, and I look forward
to working with the Board and management team in their mission to bring safe and
effective treatments to patients with food allergies and other unmet medical
needs."
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF version:
http://hugin.info/156437/R/2113599/804042.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2017 - 22:30 Uhr
Sprache: Deutsch
News-ID 548269
Anzahl Zeichen: 4693
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
